Retinal vein occlusion
Conditions
Interventions
Test group:Fariximab injection
Sponsors
Inner Mongolia Chaoyu Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female individuals aged 18 years or above. 2. Patients diagnosed with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). 3. The best corrected visual acuity (BCVA) of the affected eye is between 20/40 and 20/320. 4. Agree to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Any other ocular diseases or systemic diseases may affect the assessment of vision. 2. Patients who have received any anti-VEGF drugs or laser treatment within the past 3 months. 3. Patients who are allergic to fraxinib or any of its components. 4. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The average value of the best corrected visual acuity (BCVA) change (compared with the baseline);the change in central retinal thickness (CRT); | — |
Secondary
| Measure | Time frame |
|---|---|
| The average value of the best corrected visual acuity (BCVA) change (compared with the baseline);The proportion of patients whose visual acuity improved by =15 letters;Adverse events and serious adverse events that occurred during the treatment period;the change in central retinal thickness (CRT); | — |
Countries
China
Contacts
Public ContactGuisen Zhang
Inner Mongolia Chaoyu Eye Hospital
Outcome results
None listed